Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,214 total articles
InflaRx N.V. announced its second quarter 2026 financial results alongside key clinical and strategic updates. The company is advancing its oral C5aR inhibitor, izicopan, targeting ANCA-associated vasculitis (AAV) and select renal diseases, with Phase 2 clinical preparations ongoing. InflaRx is exploring regulatory strategies following the European…
Nayax Ltd., a Nasdaq-listed global commerce enablement and payments platform, has filed an application with the Connecticut Department of Banking to establish Nayax America Bank Inc., a non-depository innovation bank headquartered in Connecticut. The new bank, owned by Nayax USA Holdings, aims to offer embedded financial services such as corporate …
SAB Biotherapeutics reports Q2 2026 financial results highlighting progress in their SAB-142 immunotherapy for type 1 diabetes. The SAFEGUARD Phase 2b trial is on track with over 60 clinical sites activated and enrollment expected to complete by Q4 2026, with topline data anticipated in the second half of 2027. The company also secured a grant for …
Compass Therapeutics reported second quarter 2026 financial results and provided corporate updates, highlighting positive tovecimig Phase 2/3 data and expected FDA feedback this quarter. The company is advancing clinical trials for several bispecific antibody candidates targeting cancers, including expansions for CTX-8371 and initiation of CTX-471 …
Kelly Services, a specialty talent solutions provider listed on Nasdaq, announced its second-quarter 2026 results showing a 5.8% year-over-year revenue decline with improving trends across its Enterprise Talent Management (ETM) and Science, Engineering & Technology (SET) segments. Operating earnings were $16.1 million with adjusted EBITDA margin im…
Lexicon Pharmaceuticals completed enrollment for its pivotal Phase 3 SONATA-HCM study investigating sotagliflozin for hypertrophic cardiomyopathy, expects topline results in Q1 2027, and is nearing completion of NDA resubmission activities for ZYNQUISTA® in type 1 diabetes. The company also reported a net loss for Q2 2026 driven by increased R&D sp…
Cronos Group reported its second quarter 2026 results with a 51% year-over-year increase in net revenue on a constant-currency basis, driven by record revenues in Canada, Israel, and international markets like Germany. The company achieved record gross profit and Adjusted EBITDA, significantly improved net income, and reduced share count through re…
Cerenome, Inc., through its subsidiary CNSide Diagnostics, has selected XiFin Empower RCM to provide AI-driven revenue cycle management and clearinghouse services for its CNSide cerebrospinal fluid assay platform. This partnership is designed to streamline billing processes, including addressing backlog claims, and enable scalable test volume growt…
Electra Battery Materials Corporation welcomed the U.S. Department of Commerce's new rule restricting exports of battery black mass, aiming to keep critical minerals within the U.S. This aligns with Electra's strategy to develop domestic refining capacity for nickel and recycled battery materials, addressing supply chain and national security conce…
Genie Energy Ltd. announced its second quarter 2026 financial results, highlighting a decrease in revenue but strong growth in gross profit, income from operations, net income, and earnings per share. The company experienced improved gross margins driven by normalized wholesale energy market conditions and focused customer acquisition in high-value…
MACOM Technology Solutions Holdings, Inc. announced robust financial results for its fiscal third quarter ended July 3, 2026, reporting a 35.8% year-over-year increase in revenue to $342.2 million and a significant rise in net income to $100.7 million ($1.28 per diluted share), driven by strong demand in telecommunications, industrial, defense, and…
EuroDry Ltd., a drybulk vessel operator listed on NASDAQ, announced strong financial results for Q2 and H1 2026, including a net income of $6.6 million for Q2 versus a net loss of $3.1 million a year earlier. Total net revenues grew 57% in Q2 to $17.7 million, driven by a 95.6% increase in average time charter equivalent rates. Adjusted EBITDA surg…
Collegium Pharmaceutical announced its second quarter 2026 financial results, highlighting a 6% year-over-year increase in net revenues to $199.9 million. Growth was driven by a 41% increase in JORNAY PM revenue and the recent acquisition of AZSTARYS, which contributed $12.9 million in partial quarter sales. While the pain portfolio revenues declin…
Parker Hannifin Corporation announced record financial results for the fiscal 2026 fourth quarter and full year, with significant increases in sales, net income, and earnings per share. The company delivered operational excellence marked by improved segment operating margins and strong organic sales growth across all segments. Strategic acquisition…
Abeona Therapeutics Inc. will hold a conference call on August 13, 2026, to discuss its second quarter financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on developing cell and gene therapies for serious diseases, including its FDA-approved ZEVASKYN therapy for recessive dystrophic epi…
BioVie Inc. announced positive topline results from its Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage Parkinson's disease patients. The drug met its primary and secondary endpoints, showing significant improvements on motor and non-motor symptoms, beneficial effects on neuroinflammation biomarkers, and a broadly favorable proteomic …
Alterity Therapeutics, a clinical-stage biotechnology company focused on neurodegenerative diseases, announced that CEO Dr. David Stamler will present at the Canaccord Genuity Growth Conference on August 11, 2026. The company is preparing for a Phase 3 pivotal trial of ATH434 for Multiple System Atrophy (MSA), having shown positive Phase 2 results.…
Appian Corporation announced its financial results for Q2 2026, showing 19% year-over-year total revenue growth to $203.3 million driven by increased cloud subscriptions and professional services. The company improved its GAAP operating loss compared to the prior year and recorded a significant increase in non-GAAP operating income and adjusted EBI…
Lifetime Brands, Inc. announced its financial results for Q2 2026, reporting net sales growth of 7.4% year-over-year and significant earnings improvement driven by a $40.1 million tariff refund. The company repaid $40 million in term debt, showed robust growth in warehouse club and e-commerce channels, and reaffirmed net sales guidance while raisin…
Tarsus Pharmaceuticals announced robust second quarter 2026 financial results driven by 69% year-over-year growth in net product sales of their FDA-approved eye drop XDEMVY for Demodex blepharitis. The company increased its full-year sales guidance and advanced its pipeline with the pending acquisition of Alkeus Pharmaceuticals, adding a Phase 3 cl…
Tarsus Pharmaceuticals announced a $125 million private investment in public equity (PIPE) financing alongside its pending acquisition of Alkeus Pharmaceuticals. The financing garnered participation from existing and new institutional investors, supporting Tarsus' plans to advance clinical development and commercial activities primarily in ophthalm…
Ocugen provided a business update detailing FDA clearance to initiate its Phase 3 trial for OCU410 on geographic atrophy, received RMAT designation, secured a licensing agreement for OCU400 in the Middle East and North Africa, and closed a $130 million convertible senior notes financing. They remain on track for key data readouts in 2027 for their …
Iovance Biotherapeutics reported a record second quarter 2026 revenue of approximately $99 million, a 66% year-over-year increase, driven primarily by strong demand for its commercial product Amtagvi in the U.S. The company improved its gross margin to 56% and is reviewing its full-year 2026 revenue guidance upwards. Clinical progress includes FDA …
Safe Pro Group Inc., a Nasdaq-listed developer of AI-enabled defense and security solutions, announced a $780,000 purchase order from a new Department of War Prime Contractor. The order includes edge AI threat detection technology and Blue UAS drones, with work starting in Q3 2026 and expected completion in Q1 2027. This award marks the fifth recen…
Tarsus Pharmaceuticals announced its definitive agreement to acquire Alkeus Pharmaceuticals, a private biotech focused on retinal diseases, for approximately $450 million upfront plus potential milestones and royalties. The acquisition adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational drug targeting Stargardt disease—a sig…
